share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024財年二季報
美股SEC公告 ·  2024/08/14 04:18

Moomoo AI 已提取核心訊息

Adial Pharmaceuticals reported Q2 2024 financial results with R&D expenses increasing 136% to $1.0 million and G&A expenses rising 22% to $1.3 million compared to Q2 2023. The company ended the quarter with $3.3 million in cash and cash equivalents, bolstered by approximately $3.8 million from warrant exercises and $411,000 from ATM equity sales during the period.The company has initiated a Phase 1 pharmacokinetic study of AD04 with an estimated cost of $1.4 million and plans to begin a Phase III study in the first half of 2025. Management expects to use $10-15 million in cash during the next twelve months for AD04 development and corporate expenses, with $5-10 million contingent on implementing accelerated development plans.Looking ahead, Adial will require additional financing to execute its overall business strategy, including two additional Phase 3 trials for AD04 estimated at $8-12 million each. The company raised an additional $3.7 million in July 2024 through ATM equity sales, though management notes current cash is not sufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
Adial Pharmaceuticals reported Q2 2024 financial results with R&D expenses increasing 136% to $1.0 million and G&A expenses rising 22% to $1.3 million compared to Q2 2023. The company ended the quarter with $3.3 million in cash and cash equivalents, bolstered by approximately $3.8 million from warrant exercises and $411,000 from ATM equity sales during the period.The company has initiated a Phase 1 pharmacokinetic study of AD04 with an estimated cost of $1.4 million and plans to begin a Phase III study in the first half of 2025. Management expects to use $10-15 million in cash during the next twelve months for AD04 development and corporate expenses, with $5-10 million contingent on implementing accelerated development plans.Looking ahead, Adial will require additional financing to execute its overall business strategy, including two additional Phase 3 trials for AD04 estimated at $8-12 million each. The company raised an additional $3.7 million in July 2024 through ATM equity sales, though management notes current cash is not sufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
Adial Pharmaceuticals報告2024年第二季度財務結果，研發費用比2023年第二季度增加了136%，達到100萬美元，管理費用則上升22%，達到130萬美元。公司在本季度末擁有330萬美元的現金及現金等價物，資金得益於大約380萬美元的認股權證行使和41.1萬美元的ATM股票銷售。公司已啓動AD04的第一階段藥代動力學研究，預計成本爲140萬美元，並計劃於2025年上半年啓動第三階段研究。管理層預計在未來十二個月內將使用1000萬至1500萬美元的現金用於AD04開發和公司費用，其中500萬至1000萬美元將取決於加速開發計劃的實施。展望未來，Adial將需要額外融資以執行其整體業務策略，包括預計需要800萬至1200萬美元的兩個額外的AD04第三階段試驗。公司在2024年7月通過ATM股票銷售再融資370萬美元，儘管管理層指出當前現金不足以支持公司在未來十二個月的運營，這對其作爲持續經營的能力產生了重大懷疑。
Adial Pharmaceuticals報告2024年第二季度財務結果，研發費用比2023年第二季度增加了136%，達到100萬美元，管理費用則上升22%，達到130萬美元。公司在本季度末擁有330萬美元的現金及現金等價物，資金得益於大約380萬美元的認股權證行使和41.1萬美元的ATM股票銷售。公司已啓動AD04的第一階段藥代動力學研究，預計成本爲140萬美元，並計劃於2025年上半年啓動第三階段研究。管理層預計在未來十二個月內將使用1000萬至1500萬美元的現金用於AD04開發和公司費用，其中500萬至1000萬美元將取決於加速開發計劃的實施。展望未來，Adial將需要額外融資以執行其整體業務策略，包括預計需要800萬至1200萬美元的兩個額外的AD04第三階段試驗。公司在2024年7月通過ATM股票銷售再融資370萬美元，儘管管理層指出當前現金不足以支持公司在未來十二個月的運營，這對其作爲持續經營的能力產生了重大懷疑。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Portage Biotech
    PRTG
    -- 9.500
    萊斯康製藥
    LXRX
    -- 0.629
    DBV Technologies
    DBVT
    -- 5.700
    NeOnc Technologies
    NTHI
    -- 16.740
    Sensei Biotherapeutics
    SNSE
    -- 0.561
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點